About Palladio biosciences
Our lead drug candidate is lixivaptan, an investigational agent in Phase 3 development for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
There is currently only one approved product available for the more than 140,000 patients diagnosed with ADPKD in the US. The current product has been associated with liver toxicity and requires frequent blood tests to monitor for liver toxicity. We are conducting clinical trials to determine if lixivaptan may be a safe and effective treatment for patients with ADPKD, without the liver safety issues associated with the current approved treatment.
Polycystic Kidney Disease
Palladio is actively studying the safety and efficacy of lixivaptan, an investigational agent, as well as its potential to deliver a differentiated safety profile for patients with ADPKD.
Lixivaptan is a new chemical entity that is designed to work by selectively blocking (antagonizing) the action of the hormone vasopressin at the V2 receptor. Extensive clinical trials have proven that vasopressin V2 antagonists can effectively treat ADPKD.
The development program for lixivaptan is designed to show that lixivaptan can slow the decline in renal function that is typically observed in ADPKD. We believe that early therapy initiation with a vasopressin V2 antagonist could delay by several years, or possibly eliminate altogether, the need for dialysis or kidney transplant in many ADPKD patients.